Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Entresto is an angiotensin-receptor/neprilysin inhibitor (ARNI). Japanese strength notation must not be equated with valsartan alone.
Read source section ↗Mechanism of action
Sacubitril inhibits neprilysin; valsartan blocks angiotensin-II AT1 receptors.
Read source section ↗Japanese indications & eligibility
Chronic heart failure uses include adult and pediatric formulations; hypertension approval is for 100/200 mg tablets.
Read source section ↗Administration & dose differences
Heart failure usually starts at 50 mg twice daily and is titrated; hypertension usually uses 200 mg once daily.
Read source section ↗Adverse effects & key risks
Watch for angioedema, hyperkalemia, renal dysfunction and hypotension.
Read source section ↗Contraindications & special populations
Do not use with ACE inhibitors or within 36 hours of stopping them; other contraindications include angioedema history, severe hepatic impairment and pregnancy.
Read source section ↗Drug interactions
Review ACE inhibitors, other ARBs, potassium-raising agents, NSAIDs and lithium.
Read source section ↗Assessment & monitoring
Monitor blood pressure, creatinine, potassium, weight and symptoms, especially during titration.
Read source section ↗Storage & handling
Store at room temperature and protect from moisture. The photo shows adult 50 mg tablets only.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-10.
- Manufacturer information ↗www.pro.novartis.com
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
